Lentiviral Vector–Mediated Genetic Modification of Cell Substrates for the Manufacture of Proteins and Other Biologics

References

1. 1.↵
   1. Tiscornia G.,
   2. Singer O.,
   3. Ikawa M.,
   4. Verma I. M.

   A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. USA 2003, 100 (4), 1844–1848.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Cartier N.,
   2. Hacein-Bey-Abina S.,
   3. Bartholomae C. C.,
   4. Veres G.,
   5. Schmidt M.,
   6. Kutschera I.,
   7. Vidaud M.,
   8. Abel U.,
   9. Dal-Cortivo L.,
   10. Caccavelli L.,
   11. Mahlaoui N.,
   12. Kiermer V.,
   13. Mittelstaedt D.,
   14. Bellesme C.,
   15. Lahlou N.,
   16. Lefrere F.,
   17. Blanche S.,
   18. Audit M.,
   19. Payen E.,
   20. Leboulch P.,
   21. l'homme B.,
   22. Bougneres P.,
   23. Von Kalle C.,
   24. Fischer A.,
   25. Cavazzana-Calvo M.,
   26. Aubourg P.

   Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326 (5954), 818–823.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Levine B. L.,
   2. Humeau L. M.,
   3. Boyer J.,
   4. MacGregor R. R.,
   5. Rebello T.,
   6. Lu X.,
   7. Binder G. K.,
   8. Slepushkin V.,
   9. Lemiale F.,
   10. Mascola J. R.,
   11. Bushman F. D.,
   12. Dropulic B.,
   13. June C. H.

   Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 2006, 103 (46), 17372–17377.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Montini E.,
   2. Cesana D.,
   3. Schmidt M.,
   4. Sanvito F.,
   5. Ponzoni M.,
   6. Bartholomae C.,
   7. Sergi L. S.,
   8. Benedicenti F.,
   9. Ambrosi A.,
   10. Di Serio C.,
   11. Doglioni C.,
   12. von Kalle C.,
   13. Naldini L.

   Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 2006, 24 (6), 687–696.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Montini E.,
   2. Cesana D.,
   3. Schmidt M.,
   4. Sanvito F.,
   5. Bartholomae C. C.,
   6. Ranzani M.,
   7. Benedicenti F.,
   8. Sergi L. S.,
   9. Ambrosi A.,
   10. Ponzoni M.,
   11. Doglioni C.,
   12. von Kalle C.,
   13. Naldini L.

   The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 2009, 119 (4), 964–975.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Jones S.,
   2. Peng P. D.,
   3. Yang S.,
   4. Hsu C.,
   5. Cohen C. J.,
   6. Zhao Y.,
   7. Abad J.,
   8. Zheng Z.,
   9. Rosenberg S. A,
   10. Morgan R. A.

   Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Hum. Gene. Ther. 2009, 20 (6), 630–640.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Essono S.,
   2. Frobert Y.,
   3. Grassi J.,
   4. Creminon C.,
   5. Boquet D.

   A general method allowing the design of oligonucleotide primers to amplify the variable regions from immunoglobulin cDNA. J. Immunol. Methods 2003, 279 (1–2), 251–266.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Chinnasamy D.,
   2. Milsom M. D.,
   3. Shaffer J.,
   4. Neuenfeldt J.,
   5. Shaaban A. F.,
   6. Margison G. P.,
   7. Fairbairn L. J.,
   8. Chinnasamy N.

   Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol. J. 2006, 3, 14.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Modlich U.,
   2. Baum C.

   Preventing and exploiting the oncogenic potential of integrating gene vectors. J. Clin. Invest. 2009, 119 (4), 755–758.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Dropulic B.

    Novel lentiviral vectors for human gene therapy. Expert Opin. Investig. Drugs 1998, 7 (6), 997–1001.

    OpenUrlPubMed
11. 11.↵
    1. Humeau L. M.,
    2. Binder G. K.,
    3. Lu X.,
    4. Slepushkin V.,
    5. Merling R.,
    6. Echeagaray P.,
    7. Pereira M.,
    8. Slepushkina T.,
    9. Barnett S.,
    10. Dropulic L. K.,
    11. Carroll R.,
    12. Levine B. L.,
    13. June C. H.,
    14. Dropulic B.

    Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol. Ther. 2004, 9 (6), 902–913.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Laubach V. E.,
    2. Garvey E. P.,
    3. Sherman P. A.

    High-level expression of human inducible nitric oxide synthase in Chinese hamster ovary cells and characterization of the purified enzyme. Biochem. Biophys. Res. Commun. 1996, 218 (3), 802–807.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Manilla P.,
    2. Rebello T.,
    3. Afable C.,
    4. Lu X.,
    5. Slepushkin V.,
    6. Humeau L. M.,
    7. Schonely K.,
    8. Ni Y.,
    9. Binder G. K.,
    10. Levine B. L.,
    11. MacGregor R. R.,
    12. June C. H.,
    13. Dropulic B.

    Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum. Gene Ther. 2005, 16 (1), 17–25.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Schiff L. J.

    Review: production, characterization, and testing of banked mammalian cell substrates used to produce biological products. In Vitro Cell Dev. Biol. Anim. 2005, 41 (3–4), 65–70.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Petricciani J.,
    2. Sheets R.

    An overview of animal cell substrates for biological products. Biologicals 2008, 36 (6), 359–362.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Knezevic I.,
    2. Stacey G.,
    3. Petricciani J.,
    4. Sheets R.

    Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, April 22–23, 2009, Bethesda, MD, USA. Biologicals 2010, 38 (1), 162–169.

    OpenUrlPubMed
17. 17.↵
    World Health Organization, Requirements for the use of animal cells as in vitro substrates for the production of biologicals. World Health Organization (WHO) Technical Report. Series 878, 1998, Annex 1.